The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model
Aim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic liver diseases ca...
Saved in:
Published in | Experimental biomedical research Vol. 2; no. 2; pp. 50 - 61 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Bolu
Prof. Dr. Hayrettin Öztürk
01.04.2019
Experimental Biomedical Research |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure.
Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for
cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic
liver diseases caused either by viruses or toxins. The present study was conducted to investigate the
effects of UDCA and the selective COX-2 inhibitor celecoxib on inflammation and fibrogenesis in a
rat model of cholestasis induced by bile duct ligation (BDL).
Methods: Fifty Sprague–Dawley rats that underwent common BDL for 21 days were assigned to one
of five treatment groups (sham-operation, BDL, daily UDCA treatment following BDL, daily
celecoxib treatment following BDL, and daily celecoxib and UDCA combination treatment following
BDL). Serum and liver samples were collected after 21 days. Fibrosis, ductular proliferation, and
portal inflammation were scored in liver samples. Liver function tests were evaluated.
Results: In comparison with the control group, the BDL group showed hepatic damage as evidenced
by elevation in serum biochemical and histological changes such as ductular reaction, fibrosis, and
inflammation. These pathophysiological changes were attenuated by chronic UDCA and selective
COX-2 inhibitor celecoxib supplementation.
Conlusion: Our findings indicate that the addition of Celecoxib to UDCA reduces liver inflammation
and fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The
beneficial effects of chronic UDCA and Celecoxib supplementation may be associated with their
potential cytoprotective, anti-oxidative and anti-inflammatory effects. |
---|---|
ISSN: | 2618-6454 2618-6454 |
DOI: | 10.30714/j-ebr.2019250350 |